Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY January 2024 slide deck - over 120 panc pts studied

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 04, 2024 3:35pm

139 Views

Post# 35862042

RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

The results of over 120 pancreatic patients in ONCY's Adaptive Pancreatic Cancer studies (REO-17 and Goblet) are enough for an Accelerated Approval, followed by a confirmatory Phase 3 study by mid this year.

The Pancreatic Cancer Adaptive Phase 3 (confirmatory trial) intended to begin in mid-2024 - suggests Accelerated Approval and ONCY acquisition by Big Pharma before this timeline.

<< Previous

Bullboard Posts

Next >>

10 common investing mistakes to avoid